1. Puromycin: Somatic Cell Cloning

    Puromycin N-acetyl transferase gene (pac), of which the gene product catalyzes antibiotic puromycin, an effective inhibitor of protein synthesis, has been widely used as a dominant selection marker in embryonic stem (ES) cell-mediated transgenesis.
  2. Hygromycin B: Selective Properties

    Hygromycin B is an antibiotic used by scientists in bio-research to select cells modified by genetic engineering. It inhibits the growth of a wide range of prokaryotic and eukaryotic cells by interfering with protein synthesis. Hygromycin B allows the selection and maintenance of cells expressing the hygromycin-resistance gene.
  3. The role of abscisic acid's anti-inflammation

    Building on previous work with the botanical abscisic acida, researchers in the NutritionalImmunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs as well as in the gut.
  4. MG-132: Fighting Cancer Cells

    Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because it induces apoptosis in cancer cells but not in normal cells.
  5. Roscovitine: A Highly Selective CDK Inhibitor With Promising Oncology

    (R)-Roscovitine is often referred to as a “selective inhibitor of cyclin-dependent kinases.” Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis studies, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, viral infections, and glomerulonephritis.
  6. OUTSMARTING MRSA BACTERIA

    A 12-year-old boy who was diving for a basketball in his school gym in New York City got a cut on his arm. The incident was nothing out of the ordinary, but bacteria entered Rory Staunton’s bloodstream through the cut; he developed sepsis and died three days later. The New York Times carried the story of how rapidly the infection progressed and remained undiagnosed until it was too late.
  7. 3 Immunological applications of Resiquimod

    Resiquimod is an imidazoquinolinamine Toll-like receptor (TLR) agonist with potential immunostimulatory activity. Resiquimod binds to and activates TLRs 7 and 8, mainly on dendritic cells (DCs), macrophages, and B-lymphocytes, which results in the activation of the TLR signaling pathway and nuclear translocation of the transcription activator NF-kB another transcription factors; subsequently, the production of cytokines, especially interferon-alpha (INF-a), increases, enhancing T-helper 1 (Th1) immune responses.
  8. Proteasome Inhibitor MG132 Induces Death Receptor

    Combined treatment with a proteasome inhibitor and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising strategy for cancer therapy.
  9. PI3K/Akt/mTOR Pathway: The Main Cancer Breakthrough

    The PI3K/AKT/mTOR pathway is central to cell growth and survival, cell cycle regulation, and programmed cell death.Aberrant activation of this signaling cascade is linked to several disease states, and thus many components of the pathway are attractive targets for therapeutic intervention.
  10. Cycloheximide's Protection against Cancer

    It has been shown that cycloheximide (CHM), a well-known protein synthesis inhibitor, reduces Cytotoxicity induced by 1-B-D-arabinofuranosylcytosine, nitrogen mustard, or X-irradiation in normal cells, such as small intestine or bone marrow cells.

Items 1 to 10 of 16 total

To Top